目的：评估已发表的关于不同浓度的阿托品滴眼液延缓儿童青少年近视进展的有效性。

方法：搜集PubMed、the Cochrane Library、Embase、中国知网、维普和万方数据库内建库至2022-05阿托品滴眼液治疗儿童青少年近视的随机对照试验(RCT)。对纳入文献采用《Cochrane干预措施系统评价手册》中偏倚风险评价工具进行质量评价； 采用Review Manager 5.4软件进行Meta分析。

结果：共纳入14项RCT研究，包含3 946例儿童青少年受试者。Meta分析结果显示：与对照组相比，不同浓度阿托品滴眼液均可延缓儿童青少年近视进展。1%、0.5%、0.05%、0.02%、0.01%阿托品滴眼液组的眼轴增长量均低于对照组，差异均有统计学意义(MD=-0.34，95%CI：-0.39～-0.29，P<0.00001； MD=-0.51，95%CI：-0.79～-0.24，P=0.0003； MD=-0.17，95%CI：-0.30～-0.04，P=0.01； MD=-0.21，95%CI：-0.30～-0.11，P<0.0001； MD=-0.09，95%CI：-0.13～-0.05，P<0.0001)。0.1%阿托品滴眼液组眼轴增长量低于对照组，差异无统计学意义(MD=-0.50，95%CI：-1.28～0.28，P=0.21)。

结论：不同浓度阿托品滴眼液均可有效延缓儿童青少年近视进展，0.01%阿托品滴眼液延缓近视进展同时不良反应发生率最低。

METHODS: Randomized controlled trials(RCT)in PubMed, the Cochrane Library, Embase, CNKI, VIP and WanFang Data databases were retrieved from the creation to May 2022. The quality of the included literature was evaluated by using the bias risk evaluation tool in Cochrane Intervention System Evaluation Manual. Meta-analysis was carried out via Review Manager 5.4.

RESULTS: A total of 14 RCT studies, involving 3 946 children and adolescents. Meta-analysis showed that compared with the control group, atropine eye drops with different concentrations could delay the progression of myopia in children and adolescents. The growth of axial length of the groups with 1%, 0.5%, 0.05%, 0.02% and 0.01% atropine eye drops respectively was lower than that of the control group, the difference was statistically significant(MD=-0.34, 95%CI:-0.39～-0.29, P<0.00001; MD=-0.51, 95%CI:-0.79～-0.24, P=0.0003; MD=-0.17, 95%CI:-0.30～-0.04, P=0.01; MD=-0.21, 95%CI:-0.30～-0.11, P<0.0001; MD=-0.09, 95%CI:-0.13～-0.05, P<0.0001), while the growth of axial length of group with 0.1% atropine eye drops was lower than that of control group, the difference was not statistically significant(MD=-0.50, 95%CI:-1.28～0.28, P=0.21).

CONCLUSION: Atropine eye drops with different concentrations can effectively delay the progression of myopia in children and adolescents, while 0.01% can delay the progression of myopia with the lowest incidence of adverse reactions.